Zydus Lifesciences shares in focus on licensing deal with Synthon for generic ZEPOSIA in US market

Zydus Lifesciences signed an exclusive licensing and supply deal with Netherlands-based Synthon BV to commercialize generic Ozanimod Capsules (ZEPOSIA) in the U.S., used for multiple sclerosis treatment. Synthon, one of the first filers, has FDA tentative approval, qualifying for a 180-day exclusivity period. Zydus will handle commercialization while Synthon oversees manufacturing and supply.